Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer
作者： Yuhai Bian , Zhengshi Wang , Jia Xu , Wenyi Zhao , Hui Cao
DOI: 10.1016/J.BBRC.2015.07.001
关键词: Cancer research 、 Tumor progression 、 Biology 、 Immunology 、 mTORC1 、 Protein kinase B 、 Regulator 、 mTORC2 、 PI3K/AKT/mTOR pathway 、 Grading (tumors) 、 Immunohistochemistry
摘要: The rapamycin insensitive companion of mTOR (Rictor) is an essential subunit complex 2 (mTORC2), maintains the integrity and functions as regulator Akt full activation. Rictor has been implicated to be involved in growth progression malignancies, however, little known about its expression prognostic role gastric cancer particular. Therefore, we investigated relationship with clinical outcomes, together pAktSer473 pS6, two downstream substrates mTORC2 mTORC1, 396 tissue samples via immunohistochemistry. results showed that 74.0% 55.8% tumors were positive staining, respectively, which correlated well each other. Patients expressions had poorer overall survival relapse-free compared those negative staining. Both associated lymph node metastasis, TNM stage, WHO grading. was also tumor size, depth invasion, thrombus, while distant metastasis. In spite 67.4% rate presented tissues, no significant association observed between pS6Ser235/236, representing mTORC1 activity, clinicopathological features or prognosis. These suggest mTORC2/Rictor/pAkt may play a more important than mTORC1/pS6 progression, could act biomarker potential therapeutic target cancer.
elsevier.com
sci-hub.se 参考文章(32)
I Serrano, P C McDonald, F E Lock, S Dedhar, Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial–mesenchymal transition (EMT) Oncogene. ,vol. 32, pp. 50- 60 ,(2013) , 10.1038/ONC.2012.30
Wen G Jiang, Wen G Jiang, Runchun Lu, Andrew J Sanders, Andrew J Sanders, Xiao Liu, Guijun Jia, Wang Jia, Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course. Anticancer Research. ,vol. 33, pp. 3123- 3131 ,(2013)
Helena Pópulo, José Manuel Lopes, Paula Soares, The mTOR signalling pathway in human cancer. International Journal of Molecular Sciences. ,vol. 13, pp. 1886- 1918 ,(2012) , 10.3390/IJMS13021886
N K Agarwal, C-H Chen, H Cho, D R Boulbès, E Spooner, D D Sarbassov, Rictor regulates cell migration by suppressing RhoGDI2 Oncogene. ,vol. 32, pp. 2521- 2526 ,(2013) , 10.1038/ONC.2012.287
Masaki Kaibori, Nobuaki Shikata, Tatsuma Sakaguchi, Morihiko Ishizaki, Kosuke Matsui, Hiroya Iida, Yoshito Tanaka, Hirokazu Miki, Richi Nakatake, Tadayoshi Okumura, Katsuji Tokuhara, Kentaro Inoue, Jouji Wada, Michio Oda, Mikio Nishizawa, Masanori Kon, Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma Digestive Diseases and Sciences. ,vol. 60, pp. 919- 928 ,(2015) , 10.1007/S10620-014-3417-7
Jennifer S. Carew, Kevin R. Kelly, Steffan T. Nawrocki, Mechanisms of mTOR inhibitor resistance in cancer therapy Targeted Oncology. ,vol. 6, pp. 17- 27 ,(2011) , 10.1007/S11523-011-0167-8
Dos D Sarbassov, David A Guertin, Siraj M Ali, David M Sabatini, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science. ,vol. 307, pp. 1098- 1101 ,(2006) , 10.1126/SCIENCE.1106148
U. WAZIR, R.F. NEWBOLD, W.G. JIANG, A.K. SHARMA, K. MOKBEL, Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer. Oncology Reports. ,vol. 29, pp. 1969- 1974 ,(2013) , 10.3892/OR.2013.2346
X Wan, B Harkavy, N Shen, P Grohar, L J Helman, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. ,vol. 26, pp. 1932- 1940 ,(2007) , 10.1038/SJ.ONC.1209990
David A. Guertin, Deanna M. Stevens, Maki Saitoh, Stephanie Kinkel, Katherine Crosby, Joon-Ho Sheen, David J. Mullholland, Mark A. Magnuson, Hong Wu, David M. Sabatini, mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice Cancer Cell. ,vol. 15, pp. 148- 159 ,(2009) , 10.1016/J.CCR.2008.12.017